Cargando…

Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a very aggressive malignant type of tumor that currently lacks effective targeted therapies. In hematological malignancies, chimeric antigen receptor T (CAR-T) cells have shown very significant antitumor ability; however, in solid tumors, the efficacy is poor....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhenhui, Li, Yan, Liu, Wei, Li, Xun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970498/ https://www.ncbi.nlm.nih.gov/pubmed/31998790 http://dx.doi.org/10.1155/2020/4795171

Ejemplares similares

Engineering Axl specific CAR and SynNotch receptor for cancer therapy
por: Cho, Jang Hwan, et al.
Publicado: (2018)

Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy
por: Cho, Jang Hwan, et al.
Publicado: (2020)

AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
por: Zajac, Olivier, et al.
Publicado: (2020)

MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer
por: Wang, Wanqin, et al.
Publicado: (2017)

Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis
por: Ryan, Daniel, et al.
Publicado: (2019)

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
por: Falcone, Italia, et al.
Publicado: (2020)

Folate Receptor-Alpha Targeted 7x19 CAR-γδT Suppressed Triple-Negative Breast Cancer Xenograft Model in Mice
por: Ye, Xueshuai, et al.
Publicado: (2022)

Triple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype
por: Ji, Jianfeng, et al.
Publicado: (2023)

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
por: Bottai, Giulia, et al.
Publicado: (2016)

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells
por: Li, Li, et al.
Publicado: (2022)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022)

lncRNA GSEC Promotes the Progression of Triple Negative Breast Cancer (TNBC) by Targeting the miR-202-5p/AXL Axis
por: Zhang, Jianhua, et al.
Publicado: (2021)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
por: Wei, Heng, et al.
Publicado: (2020)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells
por: Yin, Li, et al.
Publicado: (2020)

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer
por: Janic, Branislava, et al.
Publicado: (2021)

An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer
por: Hajalirezay Yazdi, Shadan, et al.
Publicado: (2018)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement
por: Farheen, Jabeen, et al.
Publicado: (2022)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential
por: Wilson, Brooke E., et al.
Publicado: (2023)

AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer
por: Goyette, Marie-Anne, et al.
Publicado: (2019)

Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19
por: Bohan, Dana, et al.
Publicado: (2021)

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
por: Zhang, Zhiying, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
por: Volpe, Alessia, et al.
Publicado: (2020)

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
por: Hu, Zhiwei
Publicado: (2020)

Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers
por: Sun, Kai, et al.
Publicado: (2014)

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
por: Zhou, Jianxia, et al.
Publicado: (2019)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
por: Chen, Zhong, et al.
Publicado: (2015)

Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop
por: Shen, Yingying, et al.
Publicado: (2022)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
por: Beitzen-Heineke, Antonia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s2siaatphbi4trp7v6f6hn54c8